Core Insights - Over 170 pharmaceutical and biotechnology companies have been investigated by institutions since September, with a focus on innovative drug companies like Maiwei Biotech and Ganli Pharmaceutical, highlighting the importance of R&D investment and business development transactions [1][2] Group 1: Company Research and Development - Maiwei Biotech has received the highest institutional attention, with over 330 institutional investigations, and recently signed exclusive licensing and preferred stock purchase agreements for the 2MW7141 project [2] - Ganli Pharmaceutical aims to become a large multinational pharmaceutical company and has been investing in innovative drug development for about a decade, focusing on technologies like PROTAC and ADC [2] - Xingqi Eye Pharmaceutical has completed Phase I clinical trials for its SQ-22031 eye drops and is conducting Phase II trials for neurotrophic keratitis [3] Group 2: AI Applications in Pharmaceuticals - Xiangsheng Medical is integrating AI and robotics in ultrasound technology to enhance cancer screening capabilities [4] - Haoyuan Pharmaceutical is developing an AI-driven drug screening platform and aims to improve operational efficiency through AI applications in drug development [4][5] - Enhua Pharmaceutical is exploring the use of AI in early-stage drug development and plans to establish a system for this purpose [5] Group 3: Industry Trends and Future Outlook - The innovative drug sector is expected to maintain a high level of activity, with a focus on the upcoming 2025 European Society for Medical Oncology (ESMO) conference and related clinical data disclosures [6] - The Chinese pharmaceutical industry has transitioned to a new growth model, with traditional companies like Heng Rui and Han Sen successfully pivoting to innovation [6] - The trend of "innovation + internationalization" remains a core direction for the pharmaceutical sector, with ongoing policy support expected to enhance the global competitiveness of domestic innovative drug companies [6]

Core Insights - Over 170 pharmaceutical and biotechnology companies have been investigated by institutions since September, with a focus on innovative drug companies like Maiwei Biotech and Ganli Pharmaceutical, highlighting the trend of "innovation + internationalization" in the industry [1] Group 1: Company Developments - Maiwei Biotech has received the highest institutional attention, with over 330 institutional investigations, and signed exclusive licensing and preferred stock purchase agreements with Kalexo Bio for the 2MW7141 project [2][1] - Ganli Pharmaceutical aims to become a large multinational pharmaceutical company and has been investing in innovative drug development for about a decade, focusing on various disease treatment areas and technologies like PROTAC and ADC [2][1] - Xingqi Eye Medicine has completed Phase I clinical trials for its SQ-22031 eye drops and is conducting Phase II trials for neurotrophic keratitis, while also developing SQ-129 for macular edema [3][1] Group 2: AI Applications in Pharmaceuticals - Xiangsheng Medical is integrating AI technologies into ultrasound devices to enhance cancer screening capabilities, creating a collaborative system that combines AI, high-definition imaging, and robotic precision [4][1] - Haoyuan Pharmaceutical is focusing on AI in drug development, creating a one-stop drug screening platform and enhancing operational efficiency through AI algorithms [4][5] - Enhua Pharmaceutical is exploring the application of AI in early drug development and plans to establish a system for this purpose [5][1] Group 3: Industry Outlook - The innovative drug sector is expected to maintain a high level of activity, with predictions of new investment opportunities arising from clinical data disclosures and business development transactions around the 2025 ESMO conference [1][6] - The Chinese pharmaceutical industry has transitioned to new growth drivers, with traditional companies like Heng Rui and Han Sen completing their transformation into innovative firms, while new companies are emerging rapidly [6][1] - The trend of "innovation + internationalization" remains a core direction for the pharmaceutical sector, with continued policy support expected to enhance the global competitiveness of domestic innovative drug companies [6][1]

Core Viewpoint - Maiwei Biotech (688062.SH) has announced a share buyback program, indicating a commitment to returning value to shareholders through repurchase of shares [1] Summary by Categories Share Buyback Details - As of September 30, 2025, the company has repurchased a total of 202,138 shares, which represents 0.05% of the total share capital [1] - The highest price paid for the repurchased shares was RMB 58.02 per share, while the lowest price was RMB 50.00 per share [1] - The total amount spent on the buyback was RMB 10.6946 million, excluding transaction fees such as stamp duty and trading commissions [1]

迈威（上海）生物科技股份有限公司 关于以集中竞价交易方式回购股份进展的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/6/27 | | --- | --- | | 回购方案实施期限 | 年 月 日~2026 年 月 日 2025 6 26 6 25 | | 预计回购金额 | 2,500万元~5,000万元 | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 累计已回购股数 | 20.21万股 | | 累计已回购股数占总股本比例 | 0.05% | | 累计已回购金额 | 1,069.46万元 | | 实际回购价格区间 | 50.00元/股~58.02元/股 | 一、 回购股份的基本情况 迈威（上海）生物科技股份有限公司（以下简称"公司"）于 2025 年 6 月 26 日召开第二届董事会第十九次会议，审议通过了《关于以集中竞价交易方式回购 股份方案的议案》，同意公司使用自 ...

Group 1 - The company has repurchased a total of 202,100 shares, accounting for 0.05% of its total share capital [1] - The total amount spent on the share repurchase is approximately 10.6946 million yuan, with the actual repurchase price ranging from 50 yuan to 58.02 yuan per share [1] - The repurchased shares will be used for the employee stock ownership plan or equity incentive, with the total repurchase fund expected to be between 25 million and 50 million yuan [1]

证券代码：688062 证券简称：迈威生物 公告编号：2025-056 1 | 修订前内容 | 修订后内容 | | --- | --- | | 商品）。（除依法须经批准的项目外， | （除依法须经批准的项目外，凭营业执 | | 凭营业执照依法自主开展经营活动）许 | 照依法自主开展经营活动）许可项目： | | 可项目：药品生产；药品委托生产；药 | 药品生产；药品委托生产；药用辅料生 | | 用辅料生产；保健食品生产；食品生产； | 产；保健食品生产；食品生产；药品批 | | 药品批发；药品零售；药用辅料销售； | 发；药品零售；药用辅料销售；特殊医 | | 特殊医学用途配方食品生产；食品销 | 学用途配方食品生产；食品销售；食品 | | 售；食品互联网销售；药品进出口。（依 | 互联网销售；药品进出口。（依法须经 | | 法须经批准的项目，经相关部门批准后 | 批准的项目，经相关部门批准后方可开 | | 方可开展经营活动，具体经营项目以相 | 展经营活动，具体经营项目以相关部门 | | 关部门批准文件或许可证件为准） | 批准文件或许可证件为准） | 除上述条款修订之外，《公司章程》中其他内容不变，相关变更 ...

《公司章程修正案》（2025 年 10 月修订） 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司章程 指引》，结合公司实际业务开展情况，公司计划将原有经营范围中的人体基因诊 断与治疗技术开发、细胞技术研发和应用等经营范围删除，并拟对《公司章程》 相关条款进行修订，具体情况如下： 迈威（上海）生物科技股份有限公司 | 修订前内容 | 修订后内容 | | --- | --- | | 第二章 | 公司的经营宗旨和经营范围 | | 第十四条 经依法登记，公司的经营范 | 第十四条 经依法登记，公司的经营范 | | 围是：一般项目：技术服务、技术开发、 | 围是：一般项目：技术服务、技术开发、 | | 技术咨询、技术交流、技术转让、技术 | 技术咨询、技术交流、技术转让、技术 | | 推广；医学研究和试验发展；人体基因 | 推广；医学研究和试验发展；人体基因 | | 诊断与治疗技术开发；细胞技术研发和 | 诊断与治疗技术开发；细胞技术研发和 | | 应用；租赁服务（不含许可类租赁服 | 应用；租赁服务（不含许可类租赁服务）； | | 务）；第一类医疗设备租赁；第二类医 | 第一类医疗设备租赁；第二类医疗 ...

证券代码：688062 证券简称：迈威生物 公告编号：2025-057 迈威（上海）生物科技股份有限公司 关于召开2025年第二次临时股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 （二） 股东大会召集人：董事会 （三） 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 （四） 现场会议召开的日期、时间和地点 重要内容提示： 一、 召开会议的基本情况 （一） 股东大会类型和届次 2025年第二次临时股东大会 召开日期时间：2025 年 10 月 24 日 15 点 00 分 召开地点：上海市浦东新区李冰路 576 号创想园 3 号楼 103 会议室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 10 月 24 日 （六） 融资融券、转融通、约定购回业务账户和沪股通投资者的投票程序 涉及融资融券、转融通业务、约定购回业务相关账户以及沪股通投资者的投 票，应按照《上海证券交易所科创板上市公司自律监管指引第 ...

迈威（上海）生物科技股份有限公司 2025 年第二次临时股东大会会议资料 2025 年 10 月 | | | 迈威（上海）生物科技股份有限公司 2025 年第二次临时股东大会会议须知 为了维护全体股东的合法权益，保证股东在迈威（上海）生物科技股份有 限公司（以下简称"公司"）依法行使股东权利，确保 2025 年第二次临时股东 大会会议的正常秩序和议事效率，根据《中华人民共和国公司法》（以下简称 "《公司法》"）《中华人民共和国证券法》（以下简称"《证券法》"）、 中国证券监督管理委员会（以下简称"中国证监会"）《上市公司股东会规则》 以及《迈威（上海）生物科技股份有限公司公司章程》（以下简称"《公司章 程》"）《迈威（上海）生物科技股份有限公司股东大会议事规则》等有关规 定，特制定本须知，请全体出席股东大会的人员自觉遵守。 一、 为确认出席大会的股东或代理人或其他出席者的出席资格，会议工作 人员将对出席会议者的身份进行必要的核对工作，请被核对者予以配合。 二、 经公司审核后符合参加本次股东大会条件的股东（含股东代理人）、 董事、监事、高级管理人员及其他出席人员方可出席本次会议；公司有权拒绝 不符合条件的人士进 ...

Core Insights - In September, a total of 335 companies on the Sci-Tech Innovation Board were investigated by institutions, with 17 companies receiving over 100 inquiries each [1] - The most investigated companies included Juhe Materials, Maiwei Bio, Juguang Technology, Lankai Technology, and Jingzhida, with inquiry counts of 370, 340, 305, 231, and 194 respectively [1] - Key sectors attracting attention were semiconductors, automation equipment, photovoltaic equipment, specialized equipment, and bioproducts [1] Company Developments - Juhe Materials announced plans to acquire SK Enpulse's blank mask business for 68 billion KRW, aiming to enhance its strategic layout and address domestic semiconductor material shortages [2][3] - Maiwei Bio formed a partnership with Aditum Bio to establish Kalexo Bio and secured a global exclusive licensing agreement for a cardiovascular siRNA drug [2] - Zhongkong Technology introduced the concept of "industrial embodied intelligence," aiming to integrate autonomous intelligence into the entire production process [3] Sector Focus - Institutions showed significant interest in companies within the chip interconnection, optical interconnection, battery, and energy storage sectors [4] - Lankai Technology is advancing its MXC chip and PCIe Retimer chip, which are crucial for AI server applications, enhancing bandwidth and reducing latency [5][6] - Xiatuo New Energy is focusing on solid-state battery materials and has achieved stable production of oxide solid-state electrolytes [7][8] Financial Performance - Hai Moxing reported a 350 million CNY inventory impairment in the first half of the year but expects improvement in the coming quarters [9] - Mei Ai Technology anticipates a long-term increase in overall gross margin, driven by a higher proportion of consumable products and expanding overseas market share [10] - Jingchen Co. noted a significant increase in inventory due to a surge in orders, with a record shipment volume in the second quarter [10]